Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Eisai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Eisai's 2012 sales performance.

Eisai Co., Ltd.

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

Biogen and Eisai have announced that its jointly developed investigational anti-amyloid beta (Aβ) protofibril antibody, lecanemab, used to treat early Alzheimer’s disease with confirmed presence of amyloid pathology in ... Lecanmab is being evaluated

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment Dependent upon the results of this analysis, Eisai may submit for full approval at some point this year. ... Alzheimer’s disease is a progressive and devastating disease with few treatment options,” said Haruo Naito, chief executive officer at Eisai.

Biogen retracts EMA application for Alzheimer's drug Aduhelm

Biogen retracts EMA application for Alzheimer's drug Aduhelm compound.”. In an online statement, Biogen has said that it ‘will continue to advocate for patients and remains committed to research and development, as well as to its collaboration with Eisai,

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment The crucial study assessed the combination of Lenvima (lenvatinib) – a multiple receptor tyrosine kinase inhibitor administered orally as a pill, discovered by Eisai – with Merck’s anti-PD-1 therapy Keytruda ... advanced endometrial carcinoma,"

Five years needed to confirm the benefit of Aduhelm

Five years needed to confirm the benefit of Aduhelm Biogen and Eisai have announced plans for a global, phase 3 clinical trial to confirm the long-term clinical benefit of Aduhelm treatment against Alzheimer’s disease. ... Few experts question that Biogen and Eisai’s monoclonal antibody Aduhelm

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....